Gephardt Group is working Washington for Israel’s Teva Pharmaceuticals, the globe’s No. 1 producer of generic drugs.
The firm of former House majority leader and presidential hopeful Dick Gephardt handles the U.S. unit (North Wales, PA) of Teva as it tackles Food & Drug Administration/healthcare policies and international trade agreements.
Teva earned a major court victory on Jan. 14 as a federal judge ruled that it did not infringe on patents related to the painkiller OxyContin, which is marketed by Purdue Pharma.
Its executives on the same day told a financial analyst session that the company expects to win U.S. regulatory approval for a new less-frequent dosing of its multiple sclerosis drug Copaxone, which accounts for about 20 percent of overall sales and half of its profit.
That news sparked a nearly seven percent jump in Teva's stock price.
The former Congressman leads Team Teva, which includes Tom O'Donnell (Gephardt's former chief of staff), Robert Epplin (ex-legislative director to Sen. Susan Collins) and Michael Messmer (ex-staffer at the House Democratic Policy Committee).
Maggie Moran, who is well-connected in New Jersey and New York Democratic politics, has established Moxie Strategies in Asbury Park, NJ.
Husch Blackwell Strategies has added FleishmanHillard alum Michael Slatin as a principal in its public affairs group.
Rory Cooper, a veteran Republican operative and policy specialist, has joined Teneo’s Washington office as senior managing director in its strategy & communications practice.
Brian Fallon, who served as national press secretary for Hillary Clinton’s 2016 presidential run, is signing on next month as Vice President’s Kamala Harris’ campaign communications director.
TikTok is nothing more than a Chinese propaganda tool that poses “a grave threat to America’s national security and, in particular, impressionable children and young adults,” say two Congressmen who want the platform registered as a foreign agent.
Have a comment? Send it to 
No comments have been submitted for this story yet.